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Treatment of head and neck cancer (HNC) is often radical and the patient journey can be 
challenging, especially for individuals struggling with pre-existing mental health problems and 
lacking social support. Patients frequently suffer from high levels of emotional distress at some 
point prior to, during, or after treatment and their risk of suicide is markedly elevated. This 
structured review aimed to identify the extend of the problem, appropriate interventions and 
areas of future research. We found that the incidence of suicide among HNC patients was 
significantly elevated above that of the demographically matched general population. 
Furthermore, suicide risk in HNC patients was frequently higher, than for all other cancer sites. 
Despite the clear burden of suicide in HNC patients, there is an absence of evidence evaluating 
interventions to reduce suicidal ideation and suicide risk. Recommendations for practice are 
made, drawing from the wider literature on suicide prevention. 
Background 
Head and neck cancers (HNCs) are the 7th most common form of cancer globally1. In England, 
there were approximately 7601 cases of HNC diagnosed in 20112. Worryingly, this same report 
suggested that the incidence of HNC is rising, predicting a further rise in incidence of greater 
than 50% by 2025. Recent years have seen a change in the demographic of HNC patients due 
to a number of factors, including a rise in HPV-positive HNCs which tend to affect younger 
individuals and have a more favourable prognosis3. In keeping with these emerging trends in 
HNC aetiopathogenesis, there has been a concomitant increase in overall survival4. 
Consequently, renewed focus on enhanced quality of life in such patients is warranted.  
Suicide is a potentially preventable cause of mortality in HNC patients5. Risk of suicide is 
markedly elevated among HNC patients compared to many other cancer types or 
demographically matched controls6. This increased risk may relate to the associated morbidity 
that results from HNC and its treatment, including loss of masticatory function, impaired 
speech, disfigurement and associated dysphoria7. It has also been suggested that increases in 
suicide seen among cancer patients may reflect pre-cancer mental health problems8. 
Depression, anxiety and a number of psychological problems correlate strongly with lifestyle 
factors which increase HNC risk; most notably alcohol and tobacco use9. Despite widespread 
recognition that suicidal ideation and suicide is a significant problem in HNC survivors, there 
is a dearth of research evaluating interventions to identify, prevent or manage suicide risk in 
practice. It should be noted that while suicidal ideation (which ranges from “thinking about, 
considering or planning suicide”) is a risk factor for suicide, only a small proportion of those 
individuals expressing suicidal ideation will go on to commit suicide10. This review therefore 
seeks to: 
 explore the available literature to determine the prevalence and attributable mortality 
of suicide in HNC survivors 
 evaluate current practice aimed at identification of suicide or interventions to reduce 
suicide and suicidal ideation among such patients 
 identify areas of further research need 
Methods 
The literature was searched systematically using the following databases: MEDLINE via Ovid, 
CINAHL, Embase, PsycINFO and the Cochrane Central Register of Controlled Trials 
(CENTRAL), using a combination of MESH subject headings and key terms (supplemental 
information) relating to suicide or suicidal ideation in head and neck cancer patients. Studies 
which reported suicide or suicidal ideation in head and neck cancer patients (at any stage of 
diagnosis or treatment) were included. No restrictions were imposed on the date of publication, 
study design or number of participants. Only original studies published in English were 
included. Where the primary outcome of a study did not relate to HNC specifically, the study 
was included if it reported data for a cohort of HNC patients as a subgroup. Further hand-
searching of previously published reviews on the subject and in the reference lists of included 
studies was undertaken. 
Results and Discussion 
The literature search identified 364 records after removal of duplicates. These records were 
screened independently by two authors (JA, JT).  When there were disagreements regarding 
whether a paper should be included or excluded papers, two senior authors (AK,SNR) 
adjudicated to achieve consensus. Two further studies were identified through hand-searching 
of reference lists. Following screening, 37 full text records were obtained for further 
assessment, with 281 records excluded due to lack of relevance. After assessment, 18 articles 
were excluded with reasons provided (Table 1) and 19 included for further analysis. Figure 1 
summarises the study selection process.  
The majority of included studies were conducted in - or examined participants from - the USA 
(n=13). Of the remaining 6 studies, one study was conducted in Norway, Austria, Taiwan, 
England, Estonia and Canada, respectively. Fourteen of the included studies were secondary 
analyses of epidemiological databases and cancer registries. One study11 reported a 
retrospective chart review of a single OMFS oncology centre. One study12 employed a 
prospective longitudinal design, following 223 newly diagnosed HNC patients over 1 year in 
two head and neck surgery outpatient departments. Only one interventional study was 
included13. This randomised control trial evaluated the effect of citalopram to prevent major 
depressive disorder in the first 16 weeks after therapy for HNC. Although neither suicide nor 
suicidal ideation were specified outcome measures for this trial, both suicidal ideation and 
attempted suicide were reported as part of the Mini International Neuropsychiatric Interview 
(MINI) assessment tool used in this study. Of the remaining 16 studies included, 15 used 
completed suicide as the primary outcome, while in 1 study suicidal ideation was the primary 
outcome.  A summary of the characteristics and relevant findings of included studies is 
provided in Table 2. Observational studies consistently found that suicide risk was increased 
patients with any type of cancer compared with aged, sex and race-matched general population 
controls. This was frequently expressed as the standardized mortality ratio (SMR), ranging 
from 1.214 to 4.4415. In several studies comparing suicide rate by cancer site, HNC carried the 
highest suicide risks, with all studies reporting HNC as having an elevated suicide risk beyond 
all-site cancers. Estimates of SMR varied substantially between studies, ranging from 1.6714 to 
37.116. It should be noted that the high SMR reported by Massa et al.16 is considerably higher 
than has otherwise been reported. This may be related to limited analysis of SCCs within the 
study. Additionally, while cancer patient data was only recorded for the period of 2004-11, the 
general population mortality rate was generated from data spanning 1969-2014, despite 
considerable change in suicide trends over this time. Other studies within the same US cancer 
registry have found SMRs for suicide to range from 3.6617 to 6.0815. Most studies reported 
ethnicity (white), gender (male) and marital status (single, widowed or divorced) to carry an 
increased risk of suicide within the cohorts evaluated. In all such studies that explored the 
impact of time since diagnosis, the risk of suicide was highest in the first few months following 
HNC diagnosis and reduced substantially after 1 year. The discrepancy observed between 
mortality estimates from Henson et al.14 and the majority of similar population-level studies 
may reflect a number of factors. Most of the studies evaluated patient data from the US 
Surveillance, Epidemiology and End Results Program (SEER) registry. An important 
difference between the US and UK include access to firearms, which is the most common mode 
of suicide in the US 18 compared with hanging in the UK19. The US population also has a higher 
rate of depression, anxiety and substance abuse compared with the UK20, all of which may 
contribute to increased incidence of suicide. Critically, there are systematic disparities in the 
classification of death by suicide in each country. In the UK, the standard of proof for death by 
suicide was aligned with that of criminal justice, i.e. ‘beyond reasonable doubt’. This precedent 
was recently overturned in favour of a ‘balance of probability’21, but this occurred after the 
period analysed by Henson et al.14. In the US, the standard of proof required differs across 
states and depends in part on whether the assignment of cause of death is undertaken by a 
medical examiner or coroner22. It remains unclear to what extent such factors may contribute 
to the differences observed between such studies. 
A retrospective case note review by11 identified 3 patients who had completed suicide, 2 
patients who were documented as experiencing suicidal ideation, and 4 patients who refused 
further treatment or counselling, out of a total of 241 HNC patients seen over 5 years at a single 
US OMFS oncology centre. It is important to note that screening for suicidal ideation was not 
common practice during the time evaluated, so was likely underestimated. The authors 
identified hopelessness as a significant factor that may have triggered the 3 suicides, each of 
which could only be elucidated by an in-depth evaluation of the patients personal and social 
circumstances, preferences and values. Of note, all 3 patients who completed suicide were 
married with children and were reported to have strong social support in place. The small 
sample size evaluated limits the strength of any inferences that can be made from this 
observation but highlights the importance of individual context that is frequently lost in 
population-level assessments. 
Henry et al.12 conducted a prospective longitudinal study, consecutively recruiting 223 patients 
within the first 2 weeks of HNC diagnosis for 1 year. Participants completed a number of 
psychological tests, including the Beck Scale for Suicidal Ideation. They found a 1-year 
prevalence for suicidal ideation of 15.7% (n=35). Of these 35 suicidal patients, 71.4% (n=25) 
were assessed as at low risk for suicide, 20% (n= 7) at medium risk and 8.6% (n= 3) at high 
risk of suicide. During the study period, 2 patients attempted suicide and 1 (additional) patient 
completed suicide. The suicide risk assessment category was not reported in these patients. 
Predictors of suicidality were self-reported psychiatric history and substance use as a 
mechanism of coping with HNC diagnosis. Further exploratory covariates identified as 
correlating with suicidality were reduced quality of life, increased HNC-related symptom 
burden (pain, speech impairment) and psychological distress (assessed by the Hospital Anxiety 
and Depression Scale). Importantly, the rate of suicidal ideation was approximately 4 times 
that seen in the general population, mirroring the disparity in rates of completed suicide 
observed in large-scale epidemiological studies.  
In the only intervention trial identified (n=36), Lydiatt et al.13 suggested that a 12-week dose 
of 20-40 mg citalopram was effective in preventing major depressive disorder (MDD) in the 
first 16 weeks following cancer therapy, although the effect was not statistically significant 
with the exception of an improved global mood state score (measured by Clinician Global 
Impression-Severity scale). While not a prespecified outcome, the investigators captured data 
on suicidal ideation as part of their psychological assessment tool. They identified 2 patients 
expressing suicidal ideation in the control group, while no patients displayed suicidal thoughts 
in the intervention group. No patients were reported to have attempted or completed suicide 
during the study period. Importantly, this study was underpowered for the primary outcome, 
and certainly had not been powered to detect differences in suicidal ideation. However, it is 
reasonable to assume that effective prevention of MDD might lead to reduced suicidality in the 
HNC population, as this mechanism has been demonstrated for this intervention elsewhere23.  
With the exception of Lydiatt13, there is no available evidence evaluating interventions to 
reduce suicidal ideation or suicide in HNC populations, despite a substantial body of evidence 
demonstrating that such patients are at an increased risk of suicidality. A diagnosis of cancer 
is a highly psychologically distressing event24, which can lead to substantial anxiety, 
depression and risk of suicide25. Patients diagnosed with HNC in particular may carry 
additional psychosocial burdens of loss of normal speech, masticatory function and enjoyment 
and disfigurement. These can directly impact on quality of life and lead to social isolation26, 
which may both further increase the risk of psychiatric symptoms and suicide among such 
individuals. Furthermore, the incidence pre-existing psychiatric illness, substance abuse and 
suicidality are all elevated in HNC populations27, marking this group as higher risk than the 
general population regardless of cancer diagnosis. Suicide is a complex phenomenon, that 
represents the outcome of interactions between a multitude of psychosocial, behavioural and 
physiological factors28. The majority of suicide prevention strategies in the UK have focused 
on young and middle-aged men, people in the care of mental health services, people in contact 
with the criminal justice system, people with a history of self-harm and specific occupational 
groups such as medical staff and agricultural workers29. The profile of HNC patients may not 
fall under the remit of such strategies, as patients are typically older, may not have experienced 
contact with mental health services (regardless of mental illness), nor have a known history of 
self-harm. It should be noted that while self-harm does not necessarily correlate with 
suicidality, self-harm in individuals over the age of 60 is much more likely to be ‘high intent’ 
and thus may be a more reliable indicator of suicide risk30. Where interventions have been 
targeted specifically at elderly populations, these have primarily focused on primary care or 
community outreach models of delivery. Such programmes typically include multilevel 
interventions; education about treatment options, workshops and peer support groups, 
interpersonal or behavioural psychotherapy and psychiatric medication with stringent 
monitoring31. These interventions necessitate frequent follow-up (often fortnightly or 
monthly), which would be prohibitively time-intensive for secondary care providers, 
emphasizing the need for integration of secondary care with primary care and outreach 
facilities. Of note, one meta-analysis of Japanese data32 demonstrated a lack of effectiveness 
of an intervention delivered by GMPs, while the same intervention was found to be effective 
when delivered by a clinical psychiatrist, highlighting the reliance upon suitably trained staff 
in psychosocial therapy. A short, intensive clinical intervention of nortriptyline hydrochloride 
combined with interpersonal psychotherapy showed promise in reducing suicidality, which 
was maintained with low relapse rates (up to 26%) over a subsequent period of 3 years of 
bimonthly maintenance treatment33. Where sex differences in response to interventions are 
explored, female patients are often found to respond more favourably, with little or no impact 
in male patients31. This has obvious ramifications to HNC patients, where the majority of the 
burden of suicide is found in male patients. However, no studies have directly studied suicide 
prevention in HNC cancer patients, despite the important demographic differences in such 
individuals. Similarly, there is a dearth of literature exploring the relationship between suicide-
related behaviours, such as deliberate self-harm, non-compliance with treatment and self-
neglect and suicidal ideation or attempted/completed suicide. A number of studies have 
evaluated interventions aimed at improving mood and/or quality of life in HNC patients, 
reviewed in depth in Senchak et al.34. While these studies may offer insights into the modality 
of interventions best suited to improve wellbeing and therefore decrease suicide risk in such 
patients, the overall quality of such evidence is poor, with low sample sizes, divergent outcome 
measures and short follow-up periods. No studies included suicidal ideation or suicide 
attempts/completion as explicit outcome measures, and all would certainly be underpowered 
to detect differences in these events. This knowledge gap represents an important shortfall in 
understanding and managing the complex interplay of events, cognitive and psychosocial 
processes that lead to suicide. As the event rate of completed suicides in HNC patients is 
relatively low, suicide may be perceived as a disproportionately low risk in individual units 
without formal and proactive screening to assess suicidal ideation and intent. Accurate 
assessment of treatment need, based on targeted suicide risk assessment combined with 
background factors such as history of psychiatric symptoms or care, sociodemographic factors 
and contextual factors at an individual level may allow stratification of suicide risk and 
tailoring of treatment to the needs of each patient.  
Summary of findings 
Based on the evidence available, we found that: 
 There is a significant increase in suicides in individuals with HNC that exceeds most 
other cancer types, ranging from an approximately 20% to 600% increase. 
 The most at-risk patient profile is male, Caucasian and not married, with a history of 
psychiatric illness and substance abuse.  
 Suicidal ideation among HNC patients appears to be significant, and largely 
unexplored. The degree to which such thoughts translate to attempted or completed 
suicide remains unknown. 
 There is a dearth of research evaluating interventions to reduce suicidal ideation or 
suicide risk in HNC patients. This is a significant, unmet need for this population. 
Recommendations for practice 
 Assessment of mental state, including suicide risk assessment, should constitute an 
integral part of the management of HNC patients, from the time of diagnosis to at least 
1 year following completion of therapy. Recurrent or new malignancies after primary 
therapy should ‘reset the clock’ on this screening process. 
 Effective suicide prevention requires multilevel interventions, with a significant 
component delivered through primary care or community outreach and requires expert 
input from clinical psychiatry and psychology. 
 A combination of pharmacological and psychosocial intervention, focusing on building 
peer support and resilience appears to be most effective for suicide prevention based on 
current limited evidence. 
 Further research exploring suicidal ideation and suicide in HNC patients and evaluating 
interventions to reduce suicidal thoughts and suicide risk is urgently needed to address 
this preventable competing cause of mortality. 
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Table 1: Studies included in this review 
Author(s) Study design Participants & Setting Outcomes & Effect size 
(SMR for suicide vs. 
reference population; 
95% CI unless otherwise 
specified) 
Comments 
Innos et al.35 Retrospective 
Cohort 
65,419 patients with 
any cancer vs. 
Estonian general 
population. 
Diagnosed 1983 – 
2000. 





Male 1.73 (1.45-2.01) 
Female 0.5 (0.37 - 0.6) 
Lip, oral cavity & pharynx 
Days post diagnosis:  
0-89  
Males 0.00 (0.00-7.94) 
Females 0.00 (0.00-51.16) 
90-179  
Males 7.41 (1.53-21.64) 
Females 15.18 (0.38-4.59) 
180- 364 
Males 6.2 (1.69-15.88) 
Females 0.00 (0.00– 31.31) 
Low number of suicides 
overall (197 total). Number of 
HNC patients not specified. 




490245 patients with 
any cancer vs. 
Norwegian general 
population. 
Diagnosed 1960 – 
1997. 
Secondary analysis of 
Cancer Registry of 
Norway. 
All cancers: 
589 suicides (0.0012%) 
SMR 1.48 (1.37-1.61)  




Female 3.67 (1.35-7.99) 
 
 
Low numbers of suicides 
within HNC cohort.  







1.3m patients with any 
cancer vs. USA 
general population. 
Diagnosed 1973 -2001. 
Secondary analysis of 
SEER database USA.  
All cancers: 
Suicide HR1 by gender 
Males 6.2 (5.4-7.1) 
HNC (n=80747): 
Suicide HR1 by gender 
Males 4.7 (2.98-7.3) 
Males – 99 suicides 
(0.32%) Females – 7 
suicides (0.05%) 
Factors associated with 
increased HR for suicide: 
Surgery – contraindicated 
or refused 
Site – pharyngeal 
involvement 
Stage/grade - advanced 
and less differentiated  
Marital status - single, 
widowed or divorced  
Race – white 
HNC has highest HR for 
suicide of all cancer sites, the 
highest risk of suicide for 
males and the 4th highest for 
females. 








3.5m patients with any 







Large HNC cohort. 
Up to 30 y follow-up data. 
Diagnosed 1973 – 
2002.  
Secondary analysis of 
SEER databaseUSA. 
 
SMR 3.66 (3.16-4.22) 
Male – 3.71 (3.18-4.31) 
Female – 3.23 (1.96-5.03) 
Time since diagnosis 
0-5 y 4.65 (3.92-5.48) 
5-10 y 2.23 (1.47-3.23) 
10-15 y 1.81 (0.87-3.29) 







980 patients with any 
cancer vs. USA 
general population. 
Died in 1993. 
Secondary analysis of 





Suicidal ideation as 
reported by family in the last 





AOR2 5.74 (3.04-9.98) 
Rate of reported suicidal 
ideation – 30% (n=63, 
estimated from available 
data). 
HNC has the highest AOR for 
suicidal ideation of all cancer 
sites. 
Small sample size and 
indirect method of 
ascertaining suicidal 
ideation. 
HNC grouped with 
respiratory/lung cancers – 
limited specificity. 




32487 HNC patients 
vs. USA general 
population. 
Diagnosed 1980-2007. 
Secondary analysis of 
SEER database USA. 
 
. 
Suicide prevalence by time 
period observed: 
1980-84 – 0.4% (n=3) 
1990-94 – 0.6% (n=5) 
2000-03 – 1.3% (n=8) 
2004-07 – 1.8% (n=10) 
Year of diagnosis (data for 
2000-2007 cohorts only) 
1 - 7.8 (4.6-12.4)  
2 - 3.7 (1.8-6.6) 
3 - 2.5 (0.5-7.3) 
Factors associated with 
increased suicide risk: 
Treatment - no treatment, 
radiation or surgery alone 
Site - Pharynx, oral cavity 
Stage – distant 
spread/unstaged 
Sex - Male (100% of 
suicides) 
Age - elevated for patients 
age >45 y, peaks in 55-64 y 
age group 
Marital status - single, 
divorced or widowed 
Race - white 
 
Low number of suicides 
(n=32). 









53803 patients with 
any cancer vs. Austrian 
general population. 
Diagnosed 1991 – 
2010. 
Secondary analysis of 
Cancer Incidence in 
Five Continents 
Database for cases 
diagnosed in Tyrol. 
All cancers: 
1.86 (1.57-2.19)  
HNC: 
4.73 (2.52-8.09) 
Male (n=12) - 4.92 (2.54-
8.60) 




HNC has the highest risk for 
suicide of all cancer sites. 
HNC cohort size not 
specified. 
Low number of suicides in 
HNC cohort (n=13). 




350413 HNC patients 
vs. USA general 
population. 
Diagnosed 1973 – 
2011.  
Secondary analysis of 





Male (n=757) – 3.67 (2.80-
4.53) 
Female (n=100) 1.62 (0.53-
2.71) 
857 suicides (prevalence of 
2.45 per 100000) 
Factors associated with 
increased suicide risk: 
Site – hypopharynx > larynx 
> oral cavity/oropharynx > 
nasopharynx 
Stage – regional/distant 
spread 
Treatment – radiation 
only/no treatment 
Race – white 
Marital status – Unmarried 
Time since diagnosis –5 y 
Marked elevation in suicide 
risk in first 5 y since 
diagnosis (3-5x risk vs. 5-10 
y). 
Large, well-defined cohort of 
HNC patients with up to 30 y 
follow-up data. 









64598 HNC patients 
(SCC) vs. USA general 
population 
Diagnosed 2004-11. 
Secondary analysis of 
SEER database USA. 
37.1 (26.1-48.6) 
(n=1163; prevalence 1.8%)  




diagnosis/mortality times and 
general population times – 







287901 HNC patients 
vs. USA general 
population. 
Diagnosed 1973 – 
2014. 
Secondary analysis of 
SEER database USA. 
 
1036 suicides (prevalence 
3.6 per 100000). 
Factors associated with 
increased aRR3 for suicide: 
Site – hypopharynx > 
nasopharynx > oropharynx 
> larynx 
Stage – regional 
Treatment – none 
No. of primary tumours – 
single primary 
Sex – male 
Age - ≥70 > 60-69 > 40-59 
Race – white 
Marital status – widowed 
No influence of HPV 
relatedness on suicidality. 







4.2 million patients with 
any cancer vs. USA 
general population. 
All cancers: 
4493 suicides ( prevalence 
1.1 per 100000) 
Most suicides (all cancers) in 
males  >50 years of age 
Diagnosed 2000 – 
2014. 
Secondary analysis of 




Suicide (HNC) n=404 (2.7 
per 100000) 
HNC aRR3 1.97 (1.77-2.19) 
vs. other cancer patients 
 
 
Large, well-defined HNC 
cohort directly compared 
with other cancer sites. 
Suicide rates increasing from 







2907 patients with any 
cancer vs. 52523 
Taiwan general 
population, who had 
committed suicide 
between 2000-07. 
Secondary analysis of 
the National Health 
Insurance Research 
Database Taiwan. 
Suicide (all cancers) 
n=2907 (0.68% of all 
deaths) 
Lip, oral cavity & pharynx 
n=445 (1.34% of all deaths) 
 
 
HNC has the highest risk for 
suicide of all cancer sites. 
Unusual study design with 
self-controlled samples using 







4,722,099 patients with 
any cancer vs. English 
general population. 
Diagnosed 1995 – 
2015. 





All cancers:  
2491 suicides (prevalence 
0.05%) 
SMR 1.2 (1.16-1.25) 
HNC n=176 (prevalence 
0.1%) 
SMR 1.67 (1.44-1.94) 
 
 
Large, well defined cohort. 
Only study conducted in UK. 
NB – substantial change in 
classification of suicide as 
cause of death since data 







676,470 patients with 
any cancer vs. USA 
general population 
(n=2,152,682) 
Diagnosed 1997 – 
2014. 
Secondary analysis of 
SEER database USA. 
 
All cancers: 
HR4 = 1.34 (1.22-1.48)  
Oral cancer: 
HR 2.55 (1.59-4.12) 
HNC has the highest risk for 
suicide of all cancer sites. 
Suicide rates increasing from 





218,048 HNC patients. 
Diagnosed 1973 – 
2014. 
Secondary analysis of 
SEER database USA. 
774 suicides (prevalence 
0.35%) 
Factors associated with 
increased suicide risk: 
Sex - male (91.7% of 
suicides) 
Race - caucasian (93% of 
suicides) 




Large HNC population. 
SMRs or equivalent statistics 
to quantify suicide risk not 







8,651,569 patients with 
any cancer vs. USA 
general population. 
All cancers: 
13311 suicides (prevalence 
0.15%) 
SMR 4.44 (4.33-4.55) 
HNC cohort size not 
specified. 
Diagnosed 1973 – 
2014. 
Secondary analysis of 





SMR 6.08 (5.44-6.76) 
<1 y after diagnosis 12.57 
(9.99-15.28) 
1-5 y after diagnosis 6.99 
(5.87-8.25) 
>5 y after diagnosis 4.01 
(3.31-4.81) 
Male n=74  
SMR 5.97 (5.32-6.68) 
Female n=7  
SMR 7.45 (4.95-10.77) 
Low number of suicides in 
HNC cohorts. 
Henderson 




241 HNC patients. 
Attending University of 
Maryland OMFS 
oncology service 1991 
– 1996 USA. 
Primary outcome - Suicide, 
suicidal ideation or therapy 
refusal. 
3 suicides (1.2%)  
2 patients with suicidal 
ideation (0.8%) 
4 refused treatment or 
counselling (1.7%) 
All patients who committed 
suicide were males over 40 
years of age, married with 








223 consecutive HNC 
patients seen within 2 
weeks of diagnosis at 2 
head and neck surgery 
outpatient departments 
in Canada. 
35 (15.7%) HNC patients 
suicidal <1 year from 
diagnosis. 
Suicidal ideation rates over 
time: 
 18 (8.1%) <2 weeks 
 33 (14.8%) 3 months 
 21 (9.4%) 6 months 
 23 (10.4%) 12 months 
 
Beck Scale for Suicidal 
Ideation and Structured 
Clinical Interview for DSM-
IV-TR Axis I Disorders used 







36 HNC patients. 
Randomised in 
academic outpatient 
setting USA, July 2002-
April 2005. 
Citalopram reduced MDD 
diagnosis by 19% (-59-21).  
2 patients expressing 
suicidal ideation in control 
group vs. 0 in intervention 
group. 
Intervention – 12 week 
course of 20-40 mg 
citalopram. Sixteen-week 
follow-up only. 
Study powered for 80 
patients but stopped early 











Table 2: Excluded studies 
Author(s) Study Design Reason for exclusion 
Aboumrad, Shiner 48 Root cause analyses No HNC data reported 
Hernandez Blazquez and Cruzado 49 Longitudinal No specific HNC outcomes reported 
Mallet, Huillard 50 Cross sectional No specific HNC outcomes reported 
Sengul, Kaya 51 Cross sectional No specific HNC outcomes reported 
Walker, Waters 52 Cross sectional HNC cohort not included 
Anguiano, Mayer 53 Review No primary data 
Ferlito, Haigentz 54 Review No primary data 
Friedland 55 Review No primary data 
Friedlander, Rosenbluth 56 Review No primary data 
Haisfield-Wolfe et al.57 Review No primary data 
Harris and Barraclough 58 Review No primary data 
Lydiatt, Moran 59 Review No primary data 
Purushotham, Bains 60 Review No primary data 
Shuman, Duffy 61 Review No primary data 
Smith, Shuman 62 Review No primary data 
Mahalingam and Spielmann 63 Review No primary data 
Williams 64 Review No Primary data 
Panwar, Rieke 65 Secondary analysis of RCT Suicide/suicidal ideation not reported as an outcome 
 
  
Figure 1: PRISMA Diagram66 
Records identified through 
database searching 






















Additional records identified 
through other sources 
(n = 2) 
Records after duplicates removed 
(n = 364) 
Records screened 
(n = 83) 
Records excluded 
(n = 281) 
Full-text articles assessed 
for eligibility 
(n = 37) 
Full-text articles excluded, 
with reasons 
(n = 18) 
Studies included in 
qualitative synthesis 
(n = 19) 
